Findings

What do systematic reviews say?

321 questions · 328 findings · 23 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 119 · 36.3%GRADE not reported 15 · 4.6%Very low 64 · 19.5%Low 72 · 22%Moderate 41 · 12.5%High 17 · 5.2%

Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy

Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy

Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy

Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis

It is very uncertain whether etretinate with PUVA therapy as co‐intervention changes proportion of participants with adverse effects ‐ measured over 20… compared with placebo with PUVA therapy (very low certainty).

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
RR 17 [1.11, 259.87]
1 study · 20 participants
Very low

Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy

Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Progression‐free survival · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.76 [0.63, 0.92]
502 participants
Moderate

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Tumour response · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.28 [0.92, 1.77]
1157 participants
Moderate

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Toxicity (≥ G3) · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.69 [1.19, 2.42]
1142 participants
Moderate

Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone

Overall survival† · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.81 [0.65, 1.01]
1157 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Overall survival (OS) · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Adverse events, · stage III cutaneous melanoma

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) showed no clear difference in adverse events, compared with adjuvant immunotherapy (combined ipilimumab and nivolumab) (low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 1 [0.75, 1.34]
1 study · 20 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Overall response rate (ORR), · stage III cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Time to recurrence ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Quality of life ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Death Number of deaths over 36 months · stage III and IV cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Moderate

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Adverse events, · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes adverse events, compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 8.73 [1.29, 59]
1 study · 23 participants
Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Overall response rate (ORR), · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (combined ipilimumab and nivolumab) changes overall response rate (ORR), compared with neoadjuvant immunotherapy (nivolumab) (very low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
RR 2.91 [1.02, 8.27]
1 study · 23 participants
Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Time to recurrence · stage III and IV cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

Quality of life ‐ not measured · stage III and IV cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Overall survival (OS) · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Adverse events, · stage III cutaneous melanoma

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Low